Welcome to our dedicated page for Irhythm Technologies news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on Irhythm Technologies stock.
iRhythm Technologies Inc (IRTC) delivers innovative digital cardiac monitoring solutions through its Zio System, combining wearable biosensors with AI-powered analytics. This page provides investors and healthcare professionals with direct access to official company announcements, including product updates, clinical research findings, and strategic developments shaping the future of ambulatory ECG diagnostics.
Discover timely updates on regulatory milestones, partnership agreements, and financial performance. Our curated collection ensures you stay informed about IRTC's advancements in extended cardiac monitoring technology and its growing role in preventive cardiology.
Explore press releases covering FDA clearances, peer-reviewed study validations, and operational expansions. All content is organized to highlight iRhythm's commitment to improving arrhythmia detection through cloud-connected devices and machine learning algorithms.
Bookmark this page for streamlined access to verified information about IRTC's market leadership in digital health solutions. Check back regularly to monitor how iRhythm continues to redefine patient care through clinically validated, data-driven insights.
iRhythm Technologies (NASDAQ: IRTC) announced a leadership transition in its finance department. Brice Bobzien, the current CFO, will step down on August 31, 2024, for personal reasons. He will be succeeded by Daniel Wilson, the company's Executive Vice President of Corporate Development and Investor Relations. Bobzien, who has served as CFO since 2022, will continue in an advisory role into 2025 to ensure a smooth transition.
CEO Quentin Blackford praised Bobzien's contributions in transforming iRhythm's finance organization and positioning the company for growth. Wilson, who has been with iRhythm since 2019, brings extensive experience in corporate development, strategy, and investor relations. His background includes roles at Penumbra, J.P. Morgan, and Piper Jaffray, focusing on healthcare and medical technology sectors.
iRhythm Technologies (NASDAQ: IRTC) reported strong Q2 2024 financial results, with revenue of $148.0 million, up 19.3% year-over-year. The company achieved a gross margin of 69.9%, a 40-basis point increase from Q2 2023. Key highlights include:
1. Record quarterly demand driven by growth in existing accounts and expansion into primary care channels
2. Nearing operational readiness for four European country Zio launches
3. Launch of initial phase of manufacturing automation
4. Progress on FDA warning letter remediation
iRhythm raised its fiscal year 2024 guidance, projecting revenue growth of 18% to 20%, ranging from $580 million to $590 million. The company ended the quarter with $561.5 million in unrestricted cash, cash equivalents, and marketable securities.
iRhythm Technologies (NASDAQ:IRTC), a leading digital health care company specializing in disease detection, prevention, and prediction, has announced its plans to release second quarter 2024 financial results on Thursday, August 1, 2024, after the close of trading. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors and interested parties can access a live and archived webcast of the presentation through the 'Events & Presentations' section of iRhythm's investor website at investors.irhythmtech.com.
iRhythm Technologies (NASDAQ:IRTC) announced the launch of the initial phase of its manufacturing automation plans, a significant milestone for the company. This phase involves implementing an advanced autohandler machine to automate the testing of printed circuit board assemblies (PCBAs) for the Zio monitor. This technology streamlines the testing process, enhancing operational efficiency and capacity. CEO Quentin Blackford highlighted the milestone's role in reducing costs and supporting global patient service expansion. The automation will also support future technology iterations, including next-gen mobile cardiac telemetry (MCT) products. iRhythm expects the complete manufacturing improvements to enable the production of up to 10 million units annually.
iRhythm Technologies (NASDAQ: IRTC), a leader in digital healthcare, announced its participation in the 2024 Truist Securities MedTech Conference. The company will engage in a fireside chat on June 18 at 9:20 a.m. ET. Stakeholders can access the live and archived webcast on iRhythm's investor website, providing insights into the company's strategies and innovations in disease detection and prevention.
iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare provider, will present at the William Blair 44th Annual Growth Stock Conference. The presentation is scheduled for June 5, 2024, at 11:20 a.m. Central Time. Attendees can access the live and archived webcast via the company's investor website.
iRhythm Technologies, a digital healthcare company, reported first quarter 2024 financial results with revenue of $131.9 million, an 18.4% increase from last year. Gross margin was 66.3% with cash reserves of $569.1 million. They increased their fiscal year 2024 revenue guidance to $578-$588 million. Operational highlights included over half a million registrations and collaborations to drive efficiencies. The CEO highlighted strong revenue growth, increased traction in primary care, and the potential of EKG data for clinical insights.
FAQ
What is the current stock price of Irhythm Technologies (IRTC)?
What is the market cap of Irhythm Technologies (IRTC)?
